Anti-proliferative drug-eluting stents for the treatment of coronary stenosis
Catalan Agency for Health Technology Assessment and Research
Record ID 32003000511
Catalan, English, Spanish
Authors' objectives:
The aim of this report is to conduct a systematic revision of the efficacy, effectiveness and safety of anti-proliferative drug-eluting stents for the treatment of coronary restenosis. The aim was also to ascertain how far this technology has been disseminated in Spain, its cost, legal status in terms of commercialisation and impact on the health of the population and the organisation of the health system.
Authors' results and conclusions:
There is a good-quality scientific evidence from a controlled and randomised trial that suggests that the stent with sirolimus is efficacious and safe in the prevention of angiographic restenosis and major cardiac adverse events after coronary angioplasty in de novo lesions after 6 and 12 months of follow-up, respectively.
There is low-quality scientific evidence which suggests that the slow release form of the drug is more effective than the fast form in the prevention of coronary restenosis in de novo lesions. Nevertheless, the results of both studies are based on a small number of patients selected with low risk of restenosis and with specific coronary lesions.
Authors' recommendations:
Further results from controlled and randomised trials with a longer follow-up are required to confirm the efficacy and safety of this technology and to determine its indication for another type of lesions and groups of patients. Any use of the stent with sirolimus beyond those performed in the RAVEL study would need to be performed in the framework of a controlled and randomised clinical trial.
Authors' methods:
Systematic review
Details
Project Status:
Completed
Year Published:
2003
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Spain
MeSH Terms
- Coronary Restenosis
- Drug Delivery Systems
- Stents
Contact
Organisation Name:
Agencia de Qualitat i Avaluacio Sanitries de Catalunya
Contact Address:
Antoni Parada, CAHTA, Roc Boronat, 81-95 (2nd floor), 08005 Barcelona, Spain, Tel. +34 935 513 928, Fax: +34 935 517 510
Contact Name:
direccio@aatrm.catsalut.net / aparada@aatrm.catsalut.net
Contact Email:
direccio@aatrm.catsalut.net / aparada@aatrm.catsalut.net
Copyright:
Catalan Agency for Health Technology Assessment and Research (CAHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.